Growth hormone secretagogue peptide
Ipamorelin
Ipamorelin after one dose: 50% at ~2 h, 25% at 4 h, 12.5% at 6 h.
Drawn from the half-life in the app's model, ~2 h. The model's figures
- Compound
- Ipamorelin
- Symbol
- IPA
- Family
- Growth hormone peptides
- Parts
- 14
- References
- 21
- Checked
- Last reviewed . Sources are listed below.
How Milligram users log it

4%The joint 16th most tracked compound in Milligram: of people who track compounds in Milligram logged Ipamorelin in the last 90 days.
Schedule
Logged doses
Half of people logged between 200 and 300 mcg per dose; the median was 250 mcg.
Tracked alongside
The share of people logging Ipamorelin who also logged each.
From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.
Overview
Ipamorelin is a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, described by Raun and colleagues of Novo Nordisk in the European Journal of Endocrinology in 1998.3 Their conclusion was that "ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH", where GHRP is growth hormone-releasing peptide, GHRH is growth hormone-releasing hormone and GH is growth hormone.3 That conclusion rests on rat, swine and cell experiments.3
The human studies in the sources cited are a dose-escalation study in healthy men, a phase 2 trial in 117 patients after bowel surgery, a registry entry for a phase 2 trial of 320 patients with no results posted, and a urine excretion study in one volunteer.1,4,5,6
The figures in the row at the top are the app's, and so is its grade of the evidence for ipamorelin as moderate. Dominikowski and colleagues, in Frontiers in Endocrinology in 2026, place ipamorelin in tier B and give the human evidence base for ipamorelin as "Phase I human studies and postoperative-ileus clinical development; no efficacy data in GH-related metabolic indications".7
How it works
Sources in this part
Receptor and selectivity
Sinha and colleagues write in Translational Andrology and Urology in 2020 that ipamorelin "is a synthetic pentapeptide that is a selective agonist of the ghrelin/ GHS receptor pathway" and that it "selectively binds the same GHSR-1a receptor as GHRP-2, GHRP-6, and ibutamoren".8 In pentobarbital-anaesthetised rats Raun and colleagues report an ED50 for GH release of 80 ± 42 nmol/kg for ipamorelin and 115 ± 36 nmol/kg for GHRP-6, and in conscious swine 2.3 ± 0.03 nmol/kg and 3.9 ± 1.4 nmol/kg.3
In swine, the authors write that "None of the GH secretagogues tested affected FSH, LH, PRL or TSH plasma levels", GHRP-6 and GHRP-2 raised ACTH and cortisol, and ipamorelin "did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation", a lack of effect the authors report "even at doses more than 200-fold higher than the ED50 for GH release".3 The PubMed record gives the first author's affiliation as Novo Nordisk A/S, has no funding statement and does not state the authors' own limitations.3
Other animal results
Lall and colleagues of the University of Cambridge compared twice-daily subcutaneous ipamorelin with growth hormone in GH-deficient (lit/lit) and GH-intact (+/lit and +/+) mice, in Biochemical and Biophysical Research Communications in 2001. In the +/lit and lit/lit mice ipamorelin "induced a small (15%) increase in body weight by 2 weeks, that was not further augmented by 9 weeks", and GH treatment "markedly enhanced body weight in both groups". Ipamorelin also increased fat pad weights relative to body weight in the lit/lit and +/lit mice. In GH-intact mice "Treatment with GHS, but not GH, increased serum leptin and food intake".9 The authors conclude that "GHSs increase body fat by GH-independent mechanisms that may include increased feeding"; the PubMed record lists no grant and carries the publication type "Research Support, Non-U.S. Gov't".9
Andersen and colleagues of the University of Aarhus gave 8-month-old female rats subcutaneous methylprednisolone 9 mg/kg/day, ipamorelin 100 microg/kg three times daily, or both, for 3 months. "The maximum tetanic tension was increased significantly, and the periosteal bone formation rate increased four-fold in animals injected with GC and GHS in combination, compared with the group injected with GC alone".10 CJC-1295 was not part of that study, and the PubMed record lists no grant and carries the publication type "Research Support, Non-U.S. Gov't".10
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~2 h
- Bioavailability
- 95%
- Typical dose
- 100–300 mcg/day
- Route
- SubQ
- Time to peak
- ~30 min
The app lists a half-life of about 2 hours for ipamorelin. Gobburu and colleagues report a terminal half-life of 2 hours after 15-minute infusions in healthy men, in Pharmaceutical Research in 1999.1
| Parameter | App's figure | Reported in the sources cited |
|---|---|---|
| Half-life | About 2 hours | A terminal half-life of 2 hours, a clearance of 0.078 L/h/kg and a volume of distribution at steady-state of 0.22 L/kg, after 15-minute infusions in 8 healthy men at each of 5 dose levels.1 A 2020 review's table lists "1.5–2.5 h" with subcutaneous administration, and a 2026 review's table lists "t½ ~ 2h" with the route "i.v./s.c".8,7 None of the summary texts of the sources cited reports a measurement after subcutaneous injection in people. |
| Time to peak | About 30 minutes | The summary texts of the sources cited give no time to peak for the plasma concentration. GH release peaked at 0.67 hours in the study of 15-minute infusions, with "an exponential decline to negligible GH concentration at all doses".1 The 2026 review of Dominikowski and colleagues states peak GH "approximately 40–60 minutes after administration" in a phase I study in healthy adults, and cites Gobburu and colleagues for it.7 |
| Bioavailability | 95% by subcutaneous injection | No figure for any route in people appears in the summary texts of the sources cited. After intranasal ipamorelin in the male rat the bioavailability was estimated at approximately 20%.11 |
| Distribution and elimination | Not given by the app | In the male rat after intravenous bolus injection ipamorelin showed "a systemic plasma clearance 5-fold lower than that of GHRP-6" and was "mainly excreted in the urine", and for ipamorelin and two other NNC peptides together 60-80% of the dose was recovered from bile and urine as intact peptide.11 The record gives the first author's affiliation as Novo Nordisk A/S.11 |
The chart below is an illustration from a one-compartment model with the app's half-life of 2 hours and time to peak of 30 minutes. Its twice-daily option is the schedule of the trial of Beck and colleagues, modelled with doses 12 hours apart, because the record's text gives no dose times.4 The trial gave 0.03 mg/kg intravenously, and the chart's doses are in mcg and are not the trial's doses.4
Level over 3 days
Level, as a share of the peak after one 100 mcg dose
As studied: twice daily4. As logged in Milligram: the share of people with three or more logged doses on each schedule (How Milligram users log it).
An illustration from a pharmacokinetic model using a half-life of 2 hours. It is not a measured level or a suggested dose.
Human studies
A query of PubMed on 16 November 2026 for ipamorelin in the title or summary text returned 51 records; from their titles and the summary texts read, those reporting ipamorelin given to people are Gobburu 1999, Beck 2014 and Semenistaya 2015. A query of ClinicalTrials.gov the same day returned 3 records: the two Helsinn Therapeutics trials in the table and an observational study that lists ipamorelin among several supplements.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Gobburu and colleagues, 19991 | Dose-escalation trial with 5 infusion rates | 8 healthy men at each dose level | 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutes | Dose-proportional pharmacokinetics with a terminal half-life of 2 hours; a single episode of GH release peaked at 0.67 hours and declined to negligible GH concentration at all doses; the inter-individual variability of the PD parameters was larger than that of the PK parameters. |
| Beck and colleagues, 20144,12 | Phase 2, multicenter, double-blind, placebo-controlled trial in postoperative ileus | 117 adults enrolled after small or large bowel resection; 114 in the safety and modified intent-to-treat populations, 56 given ipamorelin and 58 placebo per Sinha and colleagues8 | 0.03 mg/kg ipamorelin or placebo by intravenous infusion twice daily, postoperative day 1 to 7 or hospital discharge | Median time to first tolerated meal 25.3 h with ipamorelin and 32.6 h with placebo (p = 0.15); any treatment-emergent adverse event 87.5% with ipamorelin and 94.8% with placebo; no significant differences in the key and secondary efficacy analyses. |
| Registry entry NCT01280344, 2011 to 20145 | Phase 2, randomized, double-blind, placebo-controlled dose-finding trial after bowel resection | 320 enrolled; Helsinn Therapeutics (U.S.), Inc is the lead sponsor | 0.03 mg/kg twice daily, 0.06 mg/kg twice daily or 0.06 mg/kg three times daily, intravenous, against placebo | The record shows the study as completed and has no results posted. |
| Semenistaya and colleagues, 20156 | Urine excretion study after nasal administration, each compound given to one volunteer | 1 volunteer given ipamorelin | Dose not given in the record's text; samples collected for 2 days | Ipamorelin was metabolized intensively and excreted as parent compound with metabolites; "Ipamorelin (1-4) free acid" was detected in urine after complete withdrawal of the parent substance. |
Deeper analysis: Gobburu and colleagues, 1999
Gobburu and colleagues, with a first-author affiliation at the School of Pharmacy of the State University of New York at Buffalo, gave eight healthy men at each of five dose levels an ipamorelin infusion over 15 minutes and measured ipamorelin and GH.1 Ipamorelin "induces the release of GH at all dose levels", with a concentration for half-maximal GH stimulation (SC50) of 214 nmol/L and a maximal GH production rate of 694 mIU/L/h in their model.1 Their conclusion is that the model "provides a useful characterization of ipamorelin disposition and GH responses across a range of doses".1 The PubMed record gives the first author's affiliation only, no funding statement and no limitations, does not say whether the same men took part at each dose level, and the review of Dominikowski and colleagues cites the study as a phase I study in healthy adults.1,7
Deeper analysis: Beck and colleagues, 2014
Beck of the Ochsner Clinic Foundation, Sweeney of the University of Massachusetts Medical School, McCarter of the University of Colorado and the Ipamorelin 201 Study Group report a phase 2 trial in postoperative ileus in the International Journal of Colorectal Disease in 2014, registered as NCT00672074.4 Safety was assessed by monitoring adverse events and laboratory tests, and the key efficacy endpoint was the time from the first dose to tolerance of a standardized solid meal.4 The result was a median of 25.3 hours with ipamorelin and 32.6 hours with placebo (p = 0.15), and the authors write: "There were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses".4 Sinha and colleagues add that the first-meal and first-bowel-movement endpoints "did not reach statistical significance", and Dominikowski and colleagues write that the findings "suggested limited clinical efficacy in this setting and tempered further clinical investigation of ipamorelin for the management of postoperative ileus".8,7
The authors state: "This study was supported by Helsinn Therapeutics (US), Inc.", that their institutions "received grants from Helsinn Therapeutics (US), Inc., to conduct the study", and that they "declare no financial or proprietary conflicts of interest".4 Helsinn also supported the manuscript's development and is the registry's lead sponsor, with the registry showing the study from April 2008 to December 2009 and no results posted.4,12 The authors' own stated limitation reads "This proof of concept study was small and enrolled patients with a broad range of underlying conditions", and their conclusion reads "Ipamorelin 0.03-mg/kg twice daily for up to 7 days was well tolerated".4 The summary text does not report deaths or discontinuations.4
Doses reported in studies
No study in the summary texts of the sources cited gave ipamorelin by subcutaneous injection to people. The app lists a typical dose of 100 to 300 mcg per day by subcutaneous injection, which is the app's figure and not a dose from a study; the doses reported in the studies are intravenous infusions in mg/kg or nmol/kg, plus one nasal administration whose dose the record does not give.
| Source | Dose | Frequency | Length |
|---|---|---|---|
| Gobburu, 1999 (infusion; the 2026 review lists "IV infusion")1,7 | 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg | The 2026 review's table lists "single administration"; the PubMed record does not state the number of infusions per man | 15 minutes |
| Beck, 2014 (intravenous)4 | 0.03 mg/kg | Twice daily | Postoperative day 1 to 7 or hospital discharge |
| Registry entry NCT01280344 (intravenous)5 | 0.03 mg/kg; 0.06 mg/kg | Twice daily for both; 0.06 mg/kg also three times daily | Primary outcome time frame up to 10 days |
| Semenistaya, 2015 (nasal)6 | Not given in the record's text | Not given in the record's text | Samples collected for 2 days |
Side effects reported
In the trial of Beck and colleagues, any treatment-emergent adverse event occurred in 87.5% of the 0.03 mg/kg ipamorelin group and 94.8% of the placebo group, and the authors conclude that the dose "was well tolerated".4 The summary text does not give the types of adverse events, deaths or discontinuations.4 Sinha and colleagues write that "Adverse effects associated with treatment were rare and similar to those reported with sermorelin", and Dominikowski and colleagues' table lists "Generally favourable tolerability with no significant common adverse effects reported compared to GH therapy; no long term safety data available".8,7
FDA's category 2 page says: "A study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility", and that FDA "has not identified safety-related information regarding ipamorelin acetate via certain other injectable routes of administration".13 The page does not name the published study, and the sources cited do not show whether it is the trial of Beck and colleagues.13,4
Dominikowski and colleagues' table of endocrine and metabolic signals lists ipamorelin as "sparing" for ACTH or cortisol activation and for prolactin elevation, defining "sparing" as "absence of effect documented", and as having less appetite and body-composition effect than GHRP-2 and GHRP-6.7 A 2026 scoping review of 6 peptides, including ipamorelin and MK-677, states that "Documented risks include cardiovascular complications and metabolic dysfunction such as insulin resistance", a statement that covers the group and names MK-677 for congestive heart failure.14
Bloodwork and markers
The app lists IGF-1, blood glucose and insulin as markers. In the human studies in the table the reported measures were ipamorelin and GH concentrations (Gobburu), time to a tolerated meal with adverse events and "laboratory tests" (Beck) and urinary metabolites (Semenistaya); the summary texts do not report IGF-1, blood glucose or insulin results.1,4,6
The animal results on these markers differ by study. Malmlöf and colleagues gave rats intravenous ipamorelin at 0.4 or 1.6 mg/kg/day, four times a day for 10 days, alongside methylprednisolone, and "IGF-I levels increased".15 Johansen and colleagues gave adult female rats subcutaneous ipamorelin at 18, 90 or 450 microg/day, or vehicle, three times daily for 15 days; the longitudinal bone growth rate rose "from 42 microm/day in the vehicle group to 44, 50, and 52 microm/day in the treatment groups (P<0.0001)", with "a pronounced and dose-dependent effect on BW gain" (body weight gain), and "The treatment did not affect total IGF-I levels".16 Adeghate and colleagues, using pancreatic tissue fragments from normal and diabetic rats, report that ipamorelin "evoked significant (p<0.04) increases in insulin secretion".17 The PubMed records of the Malmlöf, Johansen and Adeghate studies carry the publication type "Research Support, Non-U.S. Gov't", and the first author's affiliation in the Malmlöf and Johansen records is Novo Nordisk A/S.15,16,17 Andersen and colleagues, cited above, list co-authors with the same names, Malmlöf K and Johansen PB, and the records do not show whether they are the same people.10,15,16
Regulatory and anti-doping status
Mavrych and colleagues list ipamorelin in a 2026 table as "Not approved; preclinical + limited human", with "No long-term safety data".18
| Body and document | What it says about ipamorelin | Scope |
|---|---|---|
| FDA, category 2 bulk drug substances (content current as of 22 April 2026)13 | Ipamorelin acetate is listed under 503B with the date added to category 2 given as September 29, 2023: compounded drugs containing it "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities", and it "contains unnatural amino acids, which add to the complexity of peptide characterization". | Category 2 under the 503B interim policy; a statement on compounded drugs |
| WADA, Prohibited List 20262 | Named as an example in S2.2.4 among "growth hormone secretagogues (GHS) and their mimetics"; the list states "All prohibited substances in this class are non-Specified Substances". | Class S2, "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)"; in effect from 1 January 2026 |
| TGA, safety advisory of 13 April 202619 | The advisory's examples of unapproved peptide products are BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295, and ipamorelin is not among them; it states that unapproved peptide products "have not been assessed by the TGA for safety, quality or effectiveness". | Statement on unapproved peptide products in general |
Doping-control laboratories have studied ipamorelin's urinary products: Semenistaya and colleagues of the Anti-Doping Center in Moscow report that "Ipamorelin (1-4) free acid" was detected in urine samples after complete withdrawal of the parent substance, and that, across the five peptides each given nasally to one volunteer, the detection window "depends on individual metabolism, drug preparation form and the way of administration".6
What is not known
A pharmacokinetic measurement of ipamorelin after subcutaneous injection in people, and a bioavailability figure for any route in people, are not described in the summary texts of the sources cited. The registry entry for the 320-patient dose-finding trial has no results posted, and the summary texts of the sources cited do not report its outcome.5
Rahman and colleagues write in a 2026 review of peptides that include ipamorelin: "Although preclinical studies are promising, there is a current lack of clinical trials".20 A 2026 scoping review of 6 peptides, including ipamorelin, states that "Human clinical studies were limited to a handful of investigations, most lacking robust controls or rigorous study designs".14
What seized powders held is a further question. Gajda and colleagues, in Drug Testing and Analysis in 2019, analysed powders seized by Danish customs and report that comparison with reference standards identified the powders as analogs of GHRP-2, GHRP-6, ipamorelin and modified GRF 1-29, the modification in all cases being "an extra glycine amino acid at the N-terminus".21 The PubMed record gives the first author's affiliation as the University of Copenhagen and no funding statement.21
Frequently asked questions
What is the half-life of ipamorelin?
Ipamorelin had a terminal half-life of 2 hours in the one human pharmacokinetic study cited, in which 8 healthy men at each of 5 dose levels received 15-minute infusions.1 The app also lists about 2 hours, and none of the summary texts of the sources cited reports a half-life measured after subcutaneous injection in people.
What is the time to peak of ipamorelin?
What is ipamorelin?
Ipamorelin is a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2.3 In animal and cell experiments, Raun and colleagues of Novo Nordisk report in 1998 that it stimulates GH release "via a GHRP-like receptor".3 A 2020 review describes it as "a synthetic pentapeptide that is a selective agonist of the ghrelin/ GHS receptor pathway".8
Is ipamorelin banned by WADA?
Is ipamorelin approved by the FDA?
What are the side effects of ipamorelin?
In the small, placebo-controlled, Helsinn-sponsored proof-of-concept trial of Beck and colleagues, any treatment-emergent adverse event occurred in 87.5% of 0.03 mg/kg ipamorelin patients and 94.8% of placebo patients, and the authors call the dose "well tolerated".4 FDA's category 2 page cites a published study that identified serious adverse events including death with intravenous ipamorelin for improving gastric motility, without naming it.13
Has ipamorelin been tested in humans?
Ipamorelin has been given to people in a dose-escalation study of healthy men, a 117-patient phase 2 trial after bowel surgery and a urine excretion study in one volunteer, with a 320-patient dose-finding trial registered without posted results.1,4,6,5 In the small, Helsinn-sponsored proof-of-concept phase 2 trial, there were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses.4
What is the bioavailability of ipamorelin?
The app lists a bioavailability of 95% by subcutaneous injection, and the summary texts of the sources cited give no figure for any route in people. After intranasal ipamorelin in the male rat the bioavailability was estimated at approximately 20%.11
Guides, tools and comparisons
- How much ipamorelin per dayA guide that answers a question on this compound.
- Calculator for IpamorelinA calculator set up for this compound.
- Ipamorelin vs tesamorelinA side-by-side with another compound.
- Ipamorelin vs sermorelinA side-by-side with another compound.
- Previous in Growth hormone peptides: IGF-1 LR3The compound before this one in the class.
- Next in Growth hormone peptides: Kisspeptin-10The compound after this one in the class.
References
- Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res 1999. PMID 10496658
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA 2026 list
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822
- Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014. Springer, DOI 10.1007/s00384-014-2030-8
- Helsinn Therapeutics (U.S.), Inc. Phase II Double-Blind Placebo-Controlled Dose Finding Study to Evaluate Safety/Efficacy of Ipamorelin Compared to Placebo for Recovery of Gastrointestinal Function in Patients Following Small or Large Bowel Resection. ClinicalTrials.gov NCT01280344. NCT01280344
- Semenistaya E, et al. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug Test Anal 2015. PMID 25869809
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol 2026. PMC13322892
- Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol 2020. PMC7108996
- Lall S, et al. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun 2001. PMID 11162489
- Andersen NB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res 2001. PMID 11735244
- Johansen PB, et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica 1998. PMID 9879640
- Helsinn Therapeutics (U.S.), Inc. A Phase II, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of Ipamorelin Compared to Placebo for the Management of Post-Operative Ileus in Patients. ClinicalTrials.gov NCT00672074. NCT00672074
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026). FDA category 2 list
- Tewari K, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med 2026. PMID 42578445
- Malmlöf K, et al. Methylprednisolone does not inhibit the release of growth hormone after intravenous injection of a novel growth hormone secretagogue in rats. Growth Horm IGF Res 1999. PMID 10629165
- Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res 1999. PMID 10373343
- Adeghate E, et al. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro Endocrinol Lett 2004. PMID 15665799
- Mavrych V, Shypilova I, Bolgova O. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Front Aging 2026. PMC13095733
- Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 April 2026. TGA advisory
- Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev 2026. PMC12753158
- Gajda AM, et al. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Test Anal 2019. PMID 30136411